Home › Parkinson's Disease › NCT07557706

Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

* Diagnosis of idiopathic PD
* Stable medication for at least 4 weeks prior to the study

Exclusion Criteria:

* Use of beta blockers
* Sustained severe hypertension (\>/= 180/110 mmHg while seated)
* Significant uncontrolled cardiac arrhythmia
* Unstable angina
* Congestive heart failure
* History of myocardial infarction
* History of seizures
* Severe cognitive impairment
* Pregnant women or women who are planning to become pregnant

About the study

The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.

What is being tested

• transcutaneous auricular vagus nerve stimulation (device)

Sponsor: University of Alabama at Birmingham · Participants: 24 · Started: Sep 15, 2025

Contact the study team

• Alexandra Evancho, DPT · Phone: 205-975-5221

Official record on ClinicalTrials.gov — NCT07557706

Locations in the U.S.

Conditions

• Parkinson's Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.